Navigation Links
Identifying subsets of patients who will respond to subsequent lines of chemotherapy
Date:10/9/2010

In a study presented at the 35th Congress of the European Society for Medical Oncology (ESMO), Dr Giovanni Bernardo from Fondazione Maugeri in Pavia, Italy, presented results that suggested it may be possible to identify subsets of metastatic breast cancer patients who are likely to respond to subsequent lines of chemotherapy.

Dr Bernardo's group analysed data from 980 women treated with chemotherapy for metastatic breast cancer in their centre between 1992 and 2006.

They found that the median overall survival grew progressively smaller for each successive chemotherapy regimen the patients were given. The time to treatment failure also shortened as each new regimen was tried, from a median of 9.2 months for first-line therapy, to 7.8 and 6.4 months for the second and third-line drugs. Beyond the third line, there was no significant decrease in the medial time to treatment failure for each successive therapy.

The researchers found that only one factor they analysed affected a patient's overall survival time. That factor was the time to treatment failure for each line of chemotherapy. In other words, the more benefit one type of therapy offered, the more benefit the subsequent therapy was likely to offer.

"The implications of our analysis for clinical practice concern the possibility of deciding which patients should be offered a third- or successive chemotherapy line, considering that there are multiple treatment options available today for metastatic disease, and increasing numbers of patients ask for more options when a particular treatment fails," said Dr Bernardo.


'/>"/>

Contact: Vanessa Pavinato
media@esmo.org
European Society for Medical Oncology
Source:Eurekalert

Page: 1

Related biology news :

1. Biomarkers for identifying infant infections
2. Identifying mega-targets for high-yield plant breeding
3. Musicians have biological advantage in identifying emotion in sound
4. Women outperform men when identifying emotions
5. A sticky solution for identifying effective probiotics
6. University of the Basque Country develops system for identifying illnesses in Paraguay
7. Identifying molecular targets for diabetes-related ED
8. Cellulosic ethanol: Expanding options, identifying obstacles
9. Identifying federal research dollars for ag
10. Scripps scientists develop test providing new pathway for identifying obesity, diabetes drugs
11. For insulin sensitive overweight patients, 1 session of exercise improves metabolic health
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... , Dec. 16, 2014 Valencell, a leader ... PerformTek biometric technology to industry leaders such as Intel, ... clinically validated, biometric wearable products. These products will be ... Las Vegas . ... accurate, flexible and robust – with the clinical data ...
(Date:12/11/2014)... Research and Markets , ... http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the addition of the ... to their offering. One major ... of multimodal biometric systems. Multimodal biometric systems utilize ... verification and identification purposes. This helps to reduce ...
(Date:12/10/2014)... , Dec. 9, 2014  Wake Forest Baptist Medical ... building for its School of Medicine. Funding for this ... capital campaign that will be publicly launched next summer. ... located in the former 60 series R.J. Reynolds Tobacco ... Quarter. Construction will begin immediately with plans to be ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
... be expensive, time-consuming for clinicians, and tedious for children, who ... number of blood draws. A new calculation eliminates many of ... be performed in a clinical setting to offer an accurate ... formula, developed from a study that will appear in the ...
... Solution Matches More Than 10 Million ... Neurotechnology, a provider of high-precision ... MegaMatcher Accelerator, a packaged hardware and ... (1:N) biometric fingerprint and face matching ...
... summit on engineering solutions to major challenges facing ... from Duke University. Topics to be addressed include ... and education and learning. The streaming event ... The summit is in response to the Grand ...
Cached Biology News:Updated formula measures kidney function more accurately 2Updated formula measures kidney function more accurately 3New MegaMatcher Accelerator Boosts Speed for High-Volume Biometric Identification and Database Duplicate Searching 2New MegaMatcher Accelerator Boosts Speed for High-Volume Biometric Identification and Database Duplicate Searching 3Live webcasting of global engineering summit 2
(Date:12/15/2014)... 15, 2014  Ascendis Pharma A/S, a biotechnology ... address significant unmet medical needs, today announced positive ... pediatric study to evaluate once-weekly TransCon Growth Hormone ... This interim analysis consists of 25 patients, representing ... the study, completing all six months of treatment. ...
(Date:12/13/2014)... and Virgin Unite Canada, the non-profit foundation of the Virgin ... Canadian entrepreneurs tackling social and environmental challenges. Today, Sir ... Centre to announce the new partnership, which includes the development ... $1 million in seed capital provided by Virgin Unite Canada ... Foundation, founded by Alison Lawton . ...
(Date:12/13/2014)... 12, 2014 The DNA Microarray ... 2013, and is expected to grow at a ... Browse through the TOC of the DNA Microarray ... and segments, with help of various tables and ... DNA Microarray market consists of instrument, consumables, and ...
(Date:12/13/2014)... The “Global Synthetic Biology Market (2013-2018)”, analyses and ... challenges. , The global synthetic biology market is ... Scientific, Inc. (U.S.), DuPont (U.S.), and Royal DSM ... ~65% of the total synthetic biology market. ... @ http://www.marketsandmarkets.com/Market-Reports/synthetic-biology-market-889.html , Thermo Fisher Scientific, ...
Breaking Biology Technology:Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4MaRS and Virgin Unite partner to invest in business as a force for good 2MaRS and Virgin Unite partner to invest in business as a force for good 3DNA Microarray Market Is Expected to Grow at a CAGR of 15.2% from 2014 to 2019 - A Report by MicroMarket Monitor 2DNA Microarray Market Is Expected to Grow at a CAGR of 15.2% from 2014 to 2019 - A Report by MicroMarket Monitor 3DNA Microarray Market Is Expected to Grow at a CAGR of 15.2% from 2014 to 2019 - A Report by MicroMarket Monitor 4Synthetic Biology Market to HIt $5.6304 Billion by 2018 - New Research Report by MarketsandMakets 2Synthetic Biology Market to HIt $5.6304 Billion by 2018 - New Research Report by MarketsandMakets 3
... PODD ), the manufacturer and marketer of ... DeSisto, Chief Executive,Officer, will participate in the Thomas ... present an overview of the Company,at 3:50 p.m. ... Four Seasons Hotel in,Boston, MA. During the ...
... DCGN ) today announced that it will host ... the Thomas Weisel Partners Annual,Healthcare Conference. The presentation ... at the Four Seasons, Boston. The webcast can be ... and those,interested in listening should log on a ...
... CAMBRIDGE, Mass., Aug. 29 Millennium,Pharmaceuticals, Inc. ... its presentation,at the Thomas Weisel Partners 2007 ... be accessed by visiting the Investors section ... (Logo: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO ) The ...
Cached Biology Technology:Thomas Weisel Partners 2007 Healthcare Conference To Webcast Millennium Presentation 2
Chicken polyclonal to QPRT ( Abpromise for all tested applications). Antigen: Synthetic peptide, corresponding to Internal sequence amino acids 123-237 of Human QPRT Entrez Gene ID: 23475 ...
Antibody Diluent for IHC 125 ml...
QPRT Antibody...
Mouse monoclonal [4C4] to Y14 ( Abpromise for all tested applications). entrezGeneID: 9939 SwissProtID: Q9Y5S9...
Biology Products: